



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Anderson, et al.

EXAMINER: Borin, Michael L

**SERIAL NUMBER: 10/635,398** 

ART UNIT: 1631

FILING DATE:

August 6, 2003

FOR:

NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

**Mail Stop IDS** 

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (5 page) in duplicate;
- 3. Copies of Cited references B2-B6, C2-C73 and;
- 4. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any additional fees that may be due to Deposit Account No.502648, Reference No. Cura 893C (21402-593C). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully resquested to contact the undersigned at 203/974-6271, New Haven, Connecticut.

Respectfully submitted,

Date: July 7, 2005

Daniel Rieger, Reg. No. 56,436

c/o CuraGen Corporation

555 Long Wharf Drive New Haven, CT 06511

Tel: (203) 974-6271 Fax: (203) 401-3351

and Kiese



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Anderson, et al. EX

EXAMINER: Borin, Michael L

SERIAL NUMBER: 10/635,398

ART UNIT: 1631

FILING DATE:

August 6, 2003

FOR:

NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

Mail Stop IDS
Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty disclosure under 37 C.F.R.§§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R.§1.97.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs, the enclosed form PTO-1449 to evidence that the cited information has been fully considered by Patent and Trademark Office during the examination of this application.



By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R.§ 1.56(b); and (3) the information cited in the Statement is, or considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statement by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 502648, Reference No.Cura 893 C (21402-593 C).

Respectfully submitted,

Date: July 7, 2005

Daniel Rieger, Reg. No. 56,436

c/o CuraGen Corporation
555 Long Wharf Drive

New Haven, CT 06511

Tel: (203) 974-6271 Fax: (203) 401-3351

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ins are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Application Number	10/635,398		
	Filing Date	08/06/2003		
SUPPLEMENTAL INFORMATION DISCLOSURE	First Named Inventor	Anderson, et al.		
STATEMENT BY APPLICANT	Group Art Unit	1631		
	Examiner Name	Borin, Michael L		
(use as many sheets as necessary)	Attorney Docket Number	Cura 893C (21402-593C)		

	U.S. PATENT DOCUMENTS								
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	ssue Date Name of Patentee(s) or Applicant(s)		Sub Class	Filing Date If Appropriate		
	A1	2002164746	N/A	Rosana Kapeller-Libermann	435	193	10/09/2001		
	A2	2002164765	N/A	Parvinder K. Punia	435	226	11/21/2001		
	А3	5,916,771	06/29/99	Hori, et al.	435	69.9	10/11/1996		
	A4	5,939,598	08/17/99	Kucherlapatt, et al.	800	25	07/30/1992		
	A5	5,958,784	09/28/99	Steven Albert Benner	436	86	03/25/1992		
	A6	6,057,101	05/02/00	Nandabalan, et al.	435	6	06/13/1997		
	A7	6,083,693	07/04/00	Nandabalan, et al.	435	6	06/14/1996		
	A8	6,291,651	09/18/01	Hemmait-Brivanlou, et al.	530	387.3	01/12/1999		

ĺ	FOREIGN PATENT DOCUMENTS								
Exam Initials	Cit e No	Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication		Translation Yes No		
-	B2	wo	200198330						
	В3	wo	200283736						
	В4	wo	2003000846						
	B5	wo	2003000918						
	B6	wo	2003002604						

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Exam initials	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.						
Shi, et al. (1992)"Molecular cloning and expression of human alveolar macrophage cathepsin elastinolytic cysteine protease." J. Biol. Chem. 267(11):7258-7262, GenBank Accession Number 442482.							
•	С3	Garman, et al. (1998)"T cell epitopes of the major allergens from dermatophagoides (house dust mite)." Patent: US5820862, GenBank Accession Number: <b>AAE11776</b> .					
	C4	Naumann, et al. (1999)"Peptides and synthetic cell membrane." Patent: US 5962638, GenBank Accession Number: <b>AAE30198</b> .					
	C5	Tseng-Law, et al. (1999)"Positive and positive/negative cell selection mediated by peptide release." Patent: US5968753, GenBank Accession Number: <b>AAE32029</b> .					

Exam	Cite	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
Initials	No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C6	Strausberg, et al. (2002)"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences." Proc. Natl. Sci. U.S.A. 99(26):16899-16903, GenBank Accession Number: AAH37303.
	C7	Strausberg, et al. (2002)" Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences." Proc. Natl. Sci. U.S.A. 99(26):16899-16903, GenBank Accession Number: AAH52469.
	C8	Bao, et al. (2002)"A complete sequence of the T. tengcongensisi Genome." Genome Res. 12(5):689-700, GenBAnk Accession Number: <b>AAM25814</b> .
	C9	da Silva, et al. (2002) Comparison of the genomes of two Xanthomonas pathogens with differing host specifities." Nature 417(6887):459-463, GenBank Accession Number: <b>AAM41675</b> .
	C10	Wiest, et al. (2002)"Identification of Peptaibols from Trichoderma virens and Cloning of a peptaibol Synthetase." J. Biol. Chem. 277(23):20862-20868, GenBank Accession Number: <b>AAM78457</b> .
	C11	Beres, et al. (2002)"Genome sequence of a serotype M3 strain of group A Streptococcus:Phage-encoded toxins, the high-virulence phenotype, and clone emergence." Proc. Natl. Acad. Sci. U.S.A. 99(15):10078-10083, GenBank Accession Number: AAM79441.
	C12	Brettin, et al. "Complete genome seeuence of Bacillus cerus E33L." Unpublished, GenBank Accession Number: <b>AAU17301</b> .
	C13	Tang, et al. (2001)"Nucleic acids encoding a range of human polypeptides, useful in genetic vaccination, testing and therapy." Patent: WO200179449, GeneScape Accession Number: AAU30543
	C14	Guitart, et al. "Selection of quasispecies variuants, induction of interferon-sensitive genes and NF-kB nuclear translocation after HCV infection of primary Tupaia hepatocytes." Unpublished, GenBank Accession Number: AAW29894.
	C15	Guitart, et al. "Selection of quasispecies variuants, induction of interferon-sensitive genes and NF-kB nuclear translocation after HCV infection of primary Tupaia hepatocytes." Unpublished, GenBank Accession Number: <b>AAW29899</b> .
	C16	Benner, S.A., (1999)"Predicting the folded structure of proteins." Patent: US5958784, GeneScape Accession Number: <b>AAY43957</b> .
	C17	Morais, et al. "A silent dissemination of hepatitis A virus infection in a childcare center in Rio de Janeiro, Brazil: Should attending children under two years be vaccinated?" Unpublished, GenBank Accession Number: AAY59634.
	C18	Hillma, et al. (2000)"New human phosphorylation effectors useful for the diagnosis, treatment and prevention of poliferative, immune and neuronal disorders." Patent: WO200006728, GeneScape Accession Number: AAY68791.
	C19	Sicheri, et al. (2002)"Novel isolated binding pocket of receptor tyrosine kinase that regulates the kinase domain of the receptor, useful for identifying modulator of the receptor for treating lymphoproliferative conditions."Patent: WO200261055, GeneScape Accession Number: ABB81188.
	C20	Sanjanwala, et al. (2002)"New isolated human enzymes (NZMS), useful for diagnosing, treating and preventing immune system, developmental, eye, metabolic, smooth muscle, neurological, pulmonary and cardiac disorders, cancer, or parasitic infectious." Patent: WO200264795, GeneScape Accession Number: ABG32380.
	C21	Zhang, et al. (2002)"Nucleic acid encoding human UDP-GalNAc: Polypeptide N-cetylgalactosaminyltransferase 10 protein is useful to diagnose, prevent and treat disorders associated with reduced or over expression of the encoded protein." Patent: EP1243660, GeneScape Accession Number: ABP53502.
	C22	Albers, et al. (2002)"New cofactors of estrogen receptor alpha, designated as CF16, CF17, CF18, CF19, CF40, CF41, and/or CF43, useful for screening of compounds for treating osteoporosis, hormonal dysfunctions, cancer or cardiovascular disease." Accession Number: ABP70158.
	C23	Burmer, et al. (2002)"New isolated antigenic peptides e.g., For G protein-coupled receptors (GPCR), useful for diagnosing and designing drugs for treating conditions in which GPCRs are involved, e.g.,

Exam	Cite	Name of Author Title (when concentrate) Bublication Volume Boards) Bublication
Initials	No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
		AIDS, Alzheimer's didease, cancer or autoimmune disease." GeneScape Accession Number: AB25P81747.
	C24	Pena, et al. (2002)"New isolated NOVX polypeptide useful for treating cardiomyopathy, atherosclerosisi, metabolic disorders, diabetes, obesity, infectious disease, anorexia, neurodegenerative disorders, Alzheimer's disease and cancer." Patent: WO200281518, GeneScape Accession Number: ABU52623.
·	C25	Rosen, et al. (2002)"New isolated polypeptide useful for diagnosing and treating immunosuppressive conditions such as autoimmune disease and Parkinson's disease." Patent: US2002168711, GeneScape Accession Number: ADB94009.
	C26	Agee, et al. (2003)"New isolated NOVX polypeptides and nucleic acid molecules useful for treating, preventing and diagnosing pathological conditions with NOVX-associated disorders, such as cancer, obesity, diabetes and inflammatory or CNS disease." GeneScape Accession Number: ADC10019.
	C27	Tang, et al. (2003)"New polynucleotide and polypeptide useful for diagnosing, preventing or treating conditions such as neurodegenerative disease, anemias, platelet disorders, wounds, burns, ulcers, osteoporosis, autoimmune diseases or cancer." GeneScape Accession Number: ADC30299.
	C28	Tang, et al. (2003)"New polynucleotide and polypeptide useful for diagnosing, preventing or treating conditions such as neurodegenerative disease, anemias, platelet disorders, wounds, burns, ulcers, osteoporosis, autoimmune diseases or cancer." GeneScape Accession Number: ADC31270.
	C29	Marquis, et al. (2003)"New human kinases and phosphatases (KPP) polypeptide, useful for preparing a composition for treating a disease associated with decreased expression or overexpression of functional KPP e.g., cancer." Patent: WO2004001008, GeneScape Accession Number: ADH48344.
	C30	Marquis, et al. (2003)"New human kinases and phosphatases (KPP) polypeptide, useful for preparing a composition for treating a disease associated with decreased expression or overexpression of functional KPP e.g., cancer." Patent: WO2004001008, GeneScape Accession Number: <b>ADH48393</b> .
	C31	Aziz, et al. (2004)"Early detection of soft tissue sarcoma comprises determining expression of a gene in a first soft tissue sample and normal soft tissue sample and comparing the gene expression, also useful in treating soft tissue sarcoma." Patent: WO2004048938, GeneScape Accession Number: ADQ21099.
	C32	Tobmatsu, et al. (1989)"Tissue-specific expression of four types of rat calmodulin-dependent protein kinase II mRNAs." J. Biol. Chem. 264(30):17907-17912, GenBank Accession Number: <b>P15791</b> .
	C33	Shi, et al. (1992)"Molecular cloning and expression of human alveoral macrophagecathepsin S, an elastinolytic cysteine protease." J. Bilo. Chem. 267(11):7258-7262, GenBank Accession Number: P25774.
	C34	Furuta, et al. (1996)"Sequence of human hexokinase III cDNA and assignment of the human hexokinase III gene (HK3) to chromosome band 5Q35.2 by fluorescence in situ hybridization." Genomics 36(1):206-209, GenBank Accession Number: <b>P52790</b> .
	C35	Stapleton, et al. (1996)"mammalian AMP-activated protein kinase subfamily ." J. Biol. Chem. 271(2):611-614< GenBank Accession Number: <b>P54645</b> .
	. C36	Yano, K. (1999) Direct Submission, GenBank Accession Number: Q13131.
	C37	Guo, et al. (2001) Submitted to the EMBL GenBank DDBJ database, SWALL (SPTR) Accession Number: Q7Z4T5.
	C38	Strausberg, et al. (2002)"Generation and initial analysis of more than 15,000 full-length human and mouse sequences." Proc. Natl.Acad. Sci. U.S.A 99:16899-16903, SWALL (SPTR) Accession Numbe Q86VS1.
	C39	LI, et al. (2002) Submitted to the EMBL GenBank DDBJ database, SWALL (SPTR) Accession Number Q86YS0.
	C40	Carninci, et al. (1999)"High-efficiency full-length cDNA cloning." Meth.Enzymol. 303:19-44, SWALL (SPTR) Accession Number: Q8CAC5.

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C41	Baker, et al. (2003) Cloning, expression, purification, and activity of dog (Canis familiaris) and monkey (Saimiri boliviensis) cathepsin S. Protein Expr. Purif. 28(1):93-101, GenBank Accession Number: Q8HY81.
	C42	Baker, et al. (2003) Cloning, expression, purification, and activity of dog (Canis familiaris) and monkey (Saimiri boliviensis) cathepsin S. Protein Expr. Purif. 28(1):93-101, GenBank Accession Number: Q8HY82.
	C43	Merla, et al. (2002)"Identification of additional transcripts in the Wiliams-Beuren syndrome critical region." Hum. Genet. 110:429-438, SWALL (SPTR) Accession Number: Q8K483.
	C44	Strausberg, et al. (2002)" Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences." Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903, SWALL (SPTR) Accession Number: Q8N1E7.
	C45	Ota, et al. (2004)"Complete sequencing and characterization of 21,243 full-length human cDNAs" Nat. Genet. 36:40-45, SWALL (SPTR) Accession Number: Q8N291.
	C46	Strausberg, et al. (2002)" Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences." Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903, SWALL (SPTR) Accession Number: Q8N464.
	C47	Merla, et al. (2002)"Identification of additional transcripts in the Wiliams-Beuren syndrome critical region." Hum. Genet. 110:429-438, SWALL (SPTR) Accession Number: <b>Q8NFV9</b> .
	C48	Deonauth, et al. (2001) Submitted to the EMBL GenBank DDBJ database. SWALL (SPTR) Accession Number: Q8UVW8.
	C49	Hashimoto, et al. (2001) Submitted to the EMBL GenBank DDBJ database. SWALL (SPTR) Accession Number: Q95KE9.
	C50	Schuldiner, et al. (1996)"ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast." SWALL (SPTR) Accession Number: <b>Q96MY9</b> .
	C51	Nakashima, et al. (1997) Cloning of a human cDNA for CTP-phosphoethanolamine cytidylyltransferase by complementation in vivo of a yeast mutent." J. Biol. Chem. 272(14)9567-9562, GenBank Accession Number: Q99447.
	C52	Lee, et al. (2001)"Discovery and mopping of ten novel G protein-coupled receptor genes." Gene 275(1):83-91, GenBank Accession Number: Q9BXC0.
	C53	Van Rompay, et al. (1999)"Identification of a novel human adenylate kinase. cDNA cloning, expression analysis, chromosome location and characterization of the recombinant protein." Eur. J. Biochem.Accession Number: Q9Y6K8.
	C54	Bhatt, H. S., B. P. Conner, et al. (2000). "Dependence of insulin secretion from permeabilized pancreatic beta-cells on the activation of Ca(2+)/calmodulin-dependent protein kinase II. A reevaluation of inhibitor studies." Biochem Pharmacol 60(11): 1655-63.
	C55	Carrasco, A. J., P. P. Dzeja, et al. (2001). "Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels." Proc Natl Acad Sci U S A 98(13): 7623-8.
	C56	Easom, R. A. (1999). "CaM kinase II: a protein kinase with extraordinary talents germane to insulin exocytosis." Diabetes 48(4): 675-84.
	C57	Elbashir, S. M., J. Martinez, et al. (2001). "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate." Embo J 20(23): 6877-88.
	C58	Elbashir, S. M., W. Lendeckel, et al. (2001). "RNA interference is mediated by 21- and 22-nucleotide RNAs." Genes Dev 15(2): 188-200.
	C59	Fukunaga, K. and E. Miyamoto (2000). "A working model of CaM kinase II activity in hippocampal long-term potentiation and memory." Neurosci Res 38(1): 3-17.
	C60	Harborth, J., S. M. Elbashir, et al. (2001). "Identification of essential genes in cultured mammalian cells using small interfering RNAs." J Cell Sci 114(Pt 24): 4557-65.

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.							
	C61	Jimenez-Chillaron, J. C., S. Telemaque-Potts, et al. (2002). "Glucokinase gene transfer to skeletal muscle of diabetic Zucker fatty rats improves insulin-sensitive glucose uptake." Metabolism 51(1): 121-6.						
	C62	Levin, B. E. (2002). "Metabolic sensors: viewing glucosensing neurons from a broader perspective." Physiol Behav 76(3): 397-401.						
	C63	Levin, B. E., A. A. Dunn-Meynell, et al. (2001). "Brain glucosensing and the K(ATP) channel." Nat Neurosci 4(5): 459-60.						
	C64	Miki, T., B. Liss, et al. (2001). "ATP-sensitive K+ channel maintenance of glucose homeostasis." Nat Neurosci 4(5)	ls in the hypo ): 507-12.	thalamus are essential for the				
	C65	<ul><li>Pittenger, M. F., A. M. Mackay, et al. (1999). "Multilineag cells." Science 284(5411): 143-7.</li></ul>	e potential of	adult human mesenchymal stem				
	C66							
	C67	Shimkets, R. A., D. G. Lowe, et al. (1999). "Gene expression analysis by transcript profiling coupled a gene database query." Nat Biotechnol 17(8): 798-803.						
	C68	Sola, C., S. Barron, et al. (2001). "The Ca2+/calmodulin system in neuronal hyperexcitability." Int J Biochem Cell Biol 33(5): 439-55.						
	C69 Tabuchi, H., H. Yamamoto, et al. (2000). "Regulation of insulin secretion by overexpression of Ca2+/calmodulin-dependent protein kinase II in insulinoma MIN6 cells." Endocrinology 141(7): 235 60.							
	C70	Tuschl, T., P. D. Zamore, et al. (1999). "Targeted mRNA degradation by double-stranded RNA in vitro." Genes Dev 13(24): 3191-7.						
	C71	Van Rompay, A. R., M. Johansson, et al. (1999). "Identification of a novel human adenylate kinase. cDNA cloning, expression analysis, chromosome localization and characterization of the recombina protein." Eur J Biochem 261(2): 509-17.						
	C72	Wilkinson, D., (2000)"Immunochemical techniques inspiremethods." The Scientist 14(8):25-28.	e developmer	nt of new antibody purification				
	C73	Yang, X. J., L. M. Kow, et al. (1999). "Hypothalamic gluco pancreatic beta-cell mechanisms." Diabetes 48(9): 1763-	ose sensor: si 72.	milarities to and differences from				
Serial No	)	s reference is not provided as it was previously cited by or si , filed, and relied u ?0 (continuation, continuation-in-part, and divisional applicati	pon for an ea					
Examine	Examiner Date							

	 	 <u> </u>	
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.